The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Open accessThe DOI matches its Crossref record; 69 of the 71 references it cites were found in a registry or an index.
Abstract
Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for the various HDAC isoenzymes. Several studies have shown that HDAC3, in particular, plays an important role in inflammation and degenerative neurological diseases, but the development of selective HDAC3 inhibitors has been challenging. This review provides an up-to-date overview of selective HDAC3 inhibitors, and aims to support the development of novel HDAC3 inhibitors in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While most HDACi tend to employ a hydroxamic acid as a ZBG, class I HDACs (particularly HDACs 1–3) tend to be the only class of HDACs inhibited by 2-amino anilides as a ZBG (Figure 4A) [9–13].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526 · cited 1×
“HDACs have the opposite effect on histone lysine residues, and deacetylation leads to a more condensed chromatin structure, making it less accessible for the transcription machinery [6,7].”
BackgroundErasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989 · cited 3×
“HDACs have been an important drug target to treat disorders where deacetylation is distorted, such as cancer, but they are also emerging as a target for other diseases, such as neurological disorders and inflammatory, cardiac, and pulmonary diseases [9].”
BackgroundFDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365 · cited 4×
“Many HDAC inhibitors have been developed, including four U.S. Food and Drug Administration (FDA) approved anticancer drugs; vorinostat (SAHA) [50], belinostat [51], panobinostat [52], and Molecules 2018, 23, 551 4 of 13 romidepsin [53] (Figure 2).”
BackgroundInfluentialThe Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Yang, X.-J., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,230 · cited 1×
“HDACs have the opposite effect on histone lysine residues, and deacetylation leads to a more condensed chromatin structure, making it less accessible for the transcription machinery [6,7].”
BackgroundWhat's Up and Down with Histone Deacetylation and Transcription?
Pazin, M. J., & Kadonaga, J. T. (1997) · Cell · doi:10.1016/s0092-8674(00)80211-1 · Cited by 821
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 711
The impact of cellular metabolism on chromatin dynamics and epigenetics
Reid, M. A., Dai, Z., & Locasale, J. W. (2017) · Nature Cell Biology · doi:10.1038/ncb3629 · Cited by 515 · cited 1×
“The histone proteins are subjected to posttranslational modifications, including methylation, acetylation, phosphorylation, and ubiquitination, which confer epigenetic regulation of gene transcription [3,4].”
BackgroundEnhanced Histone Acetylation and Transcription: A Dynamic Perspective
Clayton, A. L., Hazzalin, C. A., & Mahadevan, L. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.017 · Cited by 473 · cited 1×
“Histone acetylation is under the control of histone acetyltransferases (HATs) and histone deacetylases (HDACs) that acetylate and deacetylate the N-terminal lysine residues of histones, respectively [5].”
BackgroundVigushin, D. M., Ali, S., Pace, P., Mirsaidi, N., Ito, K., Adcock, I. M., & Coombes, R. C. (2001) · PubMed · Cited by 447
HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner
Malvaez, M., McQuown, S. C., Rogge, G. A., Astarabadi, M., Jacques, V., Carreiro, S., Rusche, J. R., & Wood, M. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213364110 · Cited by 395 · cited 1×
“08 μM for HDAC3, and a lack of potency for other HDACs at concentrations up to 15 μM [54].”
Background
Cited by
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review
Sarkar, R., Banerjee, S., Amin, S. A., Adhikari, N., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112171 · Cited by 121
Strategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Lanka, G., Begum, D., Banerjee, S., Adhikari, N., Yogeeswari, P., & Ghosh, B. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107481 · Cited by 112
Smalley, J. P., Baker, I. M., Pytel, W. A., Lin, L., Bowman, K. J., Schwabe, J. W. R., Cowley, S. M., & Hodgkinson, J. T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02179 · Cited by 85
“Notably, 22 exhibited a DC 50 value of 0.44 ± 0.03 μ M for HDAC3 and a Dmax value of 77% for HDAC3, with the least HDAC1 and HDAC2 degradation (Dmax values 41 and 18%, respectively) compared to the other three PROTACs.”
InfluentialKaliman, P. (2018) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2018.11.010 · Cited by 97
Curcio, A., Rocca, R., Alcaro, S., & Artese, A. (2024) · Pharmaceuticals · doi:10.3390/ph17050620 · Cited by 80
“Meanwhile, Suzuki et al. identified specific compounds with phenyltriazole cap groups that exhibit greater selectivity for HDAC3 when compared to other Class I members [316,317].”
Apoptosis Induction byHistone Deacetylase Inhibitors in Cancer Cells: Role of Ku70
Gong, P., Wang, Y., & Jing, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071601 · Cited by 66
“Currently, several HDAC3 inhibitors are being developed, but there is no clinically useful inhibitor available as yet [93,137].”
BackgroundThe role of HDAC3 and its inhibitors in regulation of oxidative stress and chronic diseases
He, R., Liu, B., Geng, B., Li, N., & Geng, Q. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01399-w · Cited by 75
“However, isoenzyme-selective HDAC inhibitors are infrequent: all the HDAC3 inhibitors mentioned above are o-aminoanilide derivatives, and the selectivity of most of these compounds is evaluated by measuring the IC 50 [19].”
The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury
Li, N., Xiong, R., Bo, W., & Geng, Q. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04019-6 · Cited by 67
“Most of these inhibitors are used as anticancer agents [120].”
BackgroundStamatovic, S. M., Phillips, C. M., Martínez-Revollar, G., Keep, R. F., & Andjelkovic, A. V. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00864 · Cited by 65
“The knowledge from those clinical trials may help facilitate translation of HDAC inhibitors to the clinic, as may the generation of new inhibitors of specific HDAC subtypes that might lessen drug side effects (Cao et al., 2018).”
MethodStructure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Luo, Y., & Li, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228828 · Cited by 62
“For example, Try107 in HDAC3 (serine in HDAC1 and HDAC2) causes steric hindrance and thus excludes the binding of inhibitors with large functional groups [136].”
BackgroundCurrent trends in development of HDAC-based chemotherapeutics
Cheshmazar, N., Hamzeh‐Mivehroud, M., Charoudeh, H. N., Hemmati, S., Melesina, J., & Dastmalchi, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120946 · Cited by 60
Li, L., Hao, S., Gao, M., Liu, J., Xu, X., Huang, J., Cheng, G., & Yang, H. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0317 · Cited by 70
“The involvement of HDAC3 in antitumor immunity has been extensively investigated, and the HDAC3selective inhibitors are currently considered as a potential therapeutic strategy to combat various cancers (11, 20, 21).”
BackgroundKrieger, V., Hamacher, A., Cao, F., Stenzel, K., Gertzen, C. G. W., Schäker‐Hübner, L., Kurz, T., Gohlke, H., Dekker, F. J., Kassack, M. U., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01489 · Cited by 59
Self-citationPulya, S., Patel, T. K., Paul, M., Adhikari, N., Banerjee, S., Routholla, G., Biswas, S., Jha, T., & Ghosh, B. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114470 · Cited by 56
Targeting HDAC Complexes in Asthma and COPD
Zwinderman, M. R. H., de Weerd, S., & Dekker, F. J. (2019) · Epigenomes · doi:10.3390/epigenomes3030019 · Cited by 52
“Class IIA HDACs include HDAC4, 5, 7, 9 and class IIB harbors HDAC6 and 10 and have mostly cytoplasmic functions [34,35].”
BackgroundSelf-citationPurine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors
Nepali, K., Chang, T.-Y., Lai, M.-J., Hsu, K., Yen, Y., Lin, T. E., Lee, S., & Liou, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112291 · Cited by 53
Ibrahim, H. S., Abdelsalam, M., Zeyn, Y., Zessin, M., Mustafa, A.-H. M., Fischer, M. A., Zeyen, P., Sun, P., Bülbül, E. F., Vecchio, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010369 · Cited by 50
“Meanwhile, HDAC3 has a narrower foot pocket created by pushing the L133 by Y107 in HDAC3 (replaced by S113/118 in HDAC1/2) [45], which does not allow the accommodation of bulky substituents (e.g., thiophene rings) as also substantiated by the docking results in HDAC3 (Supplementary Figure S2).”
BackgroundSu, M., Gong, X.-Y., & Liu, F. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1877656 · Cited by 47
“common HDAC3-selective tool compound [76,77].”
The HDAC3 enzymatic activity regulates skeletal muscle fuel metabolism
Song, S., Wen, Y., Tong, H. N., Loro, E., Gong, Y., Liu, J., Hong, S., Li, L., Khurana, T. S., Chu, M., et al. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy066 · Cited by 44
Schäker‐Hübner, L., Haschemi, R., Büch, T., Kraft, F. B., Brumme, B., Schöler, A., Jenke, R., Meiler, J., Aigner, A. M., Bendas, G., et al. (2022) · ChemMedChem · doi:10.1002/cmdc.202100755 · Cited by 44
The inflammatory effect of epigenetic factors and modifications in type 2 diabetes
Akbari, M., & Hassan‐Zadeh, V. (2019) · Inflammopharmacology · doi:10.1007/s10787-019-00663-9 · Cited by 35
Bresciani, A., Ontoria, J. M., Biancofiore, I., Cellucci, A., Ciammaichella, A., Di Marco, A., Ferrigno, F., Francone, A., Malancona, S., Monteagudo, E., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00517 · Cited by 32
Histone deacetylase 3 (HDAC3) as an important epigenetic regulator of kidney diseases
Zhang, L., & Cao, W. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02141-8 · Cited by 33
Serganova, I. S., Chakraborty, S., Yamshon, S., Isshiki, Y., Bucktrout, R., Melnick, A. M., Béguelin, W., & Zappasodi, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.805195 · Cited by 31
Ghiboub, M., Elfiky, A. M. I., de Winther, M. P. J., Harker, N. R., Tough, D. F., & de Jonge, W. J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050336 · Cited by 28
Abe, Y., Kofman, E. R., Almeida, M., Ouyang, Z., Ponte, F., Mueller, J. R., Cruz‐Becerra, G., Sakai, M., Prohaska, T. A., Spann, N. J., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.08.029 · Cited by 33
Kraft, F. B., Biermann, L., Schäker‐Hübner, L., Hanl, M., Hamacher, A., Kassack, M. U., & Hansen, F. K. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01817 · Cited by 28
HDAC3 in action: Expanding roles in inflammation and inflammatory diseases
He, R., He, Z., Zhang, T., Liu, B., Gao, M., Li, N., & Geng, Q. (2024) · Cell Proliferation · doi:10.1111/cpr.13731 · Cited by 27
High-Throughput Approaches onto Uncover (Epi)Genomic Architecture of Type 2 Diabetes
Dziewulska, A., Dobosz, A. M., & Dobrzyń, A. (2018) · Genes · doi:10.3390/genes9080374 · Cited by 26
“Furthermore, several epigenetic signatures, such as circulating microRNAs (miR-375 and miR-126) [61], differentially methylated circulating DNA in insulin gene promoter [62], and histone deacetylase 3 (HDAC3) inhibitors [63] have been proposed as novel tools for T2D diagnosis [61], prediction [62], and treatment [63],…”
BackgroundAbe, Y., Kofman, E. R., Ouyang, Z., Cruz‐Becerra, G., Spann, N. J., Seidman, J. S., Troutman, T. D., Stender, J. D., Taylor, H., Fan, W., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2316104121 · Cited by 22
“S3 B ) (14) revealed an overlapping profile of compromised TLR4 - dependent gene expression in RGFP966 - treated (Fig.”
InfluentialDown-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis
Zhang, M., Yin, Y., Dorfman, R. G., Zou, T., Pan, Y., Li, Y., Wang, Y., Zhou, Q., Zhou, L., Kong, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19660 · Cited by 18
Medicinal chemistry advances in targeting class I histone deacetylases
Abdallah, D. I., de Araujo, E. D., Patel, N. H., Hasan, L. S., Moriggl, R., Krämer, O. H., & Gunning, P. T. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00166 · Cited by 17
Al-Amily, D. H., & Mohammed, M. H. (2019) · Scientia Pharmaceutica · doi:10.3390/scipharm87040028 · Cited by 18
Uba, A. İ., & Zengin, G. (2023) · Amino Acids · doi:10.1007/s00726-023-03297-y · Cited by 17
“HDAC3, HDAC7, and HDAC9 are linked to the prognosis and survival in childhood acute lymphoblastic leukemia (Moreno et al. 2010).”
InfluentialKraft, F. B., Enns, J., Honin, I., Engelhardt, J., Schöler, A., Smith, S. T., Meiler, J., Schäker‐Hübner, L., Weindl, G., & Hansen, F. K. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107072 · Cited by 15
Yang, Y., Zhang, Y., Lin, Z., Wu, K., He, Z., Zhu, D., Zhao, J., Zhang, C., & Fan, Y. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02581-3 · Cited by 14
Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy
Wang, Z., He, H., Liao, X., Yuan, L., Sun, S., Xu, C., Yang, X., Zang, Q., Peng, X., Chen, J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02529 · Cited by 16
Hydroxamic acid derivatives as selective HDAC3 inhibitors: computer-aided drug design strategies
Patel, P., Shrivastava, S. K., Sharma, P. A., Kurmi, B. D., Shirbhate, E., & Rajak, H. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2192804 · Cited by 12
“HDAC3 is isoenzymes of class I and hopeful therapeutic target which play essential role in the treatment of various types of cancers as well as in multiple myeloma (Cao et al., 2018; Minami et al., 2014; Yan et al., 2018).”
BackgroundMethodRational Design and Development of HDAC Inhibitors for Breast Cancer Treatment
Mody, D., Bouckaert, J. M. J., Savvides, S. N., & Gupta, V. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210917143953 · Cited by 13
“Selectivity of inhibitors with orthoaminoanilide scaffold which are otherwise selective for HDAC1-3, can be tapered against just HDAC3 by substituting different functional groups to the pharmacophore elements (157).”
BackgroundInfluentialHDAC3 inhibitors: a patent review of their broad-spectrum applications as therapeutic agents
Makgoba, T. B., Kapp, E., Egieyeh, S. A., & Joubert, J. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2363890 · Cited by 14
“Cao et al. [56] discussed that the hydro-xamate scaffold is the common scaffold of the ZBG that determines HDAC3 specificity.”
BackgroundNiu, H., Song, W., Pei, D., Ma, C., Liu, F., Li, Y., & Han, S. (2021) · Genomics · doi:10.1016/j.ygeno.2021.12.019 · Cited by 9
Dong, L., Huang, J., Zu, P., Liu, J., Gao, X. J., Jianwei, D., & Li, Y. (2021) · Bioengineered · doi:10.1080/21655979.2021.1977557 · Cited by 10
HDAC3: A Multifaceted Modulator in Immunotherapy Sensitization
Han, R., Luo, Y., Gao, J., Zhou, H., Wang, Y., Chen, J., Zheng, G., & Ling, C. (2025) · Vaccines · doi:10.3390/vaccines13020182 · Cited by 12
“By specifically targeting the HDAC3 isoform, these inhibitors regulate pathological pathways associated with HDAC3, achieving more precise anticancer effects [54–56].”
Ashraf, R., Adel, M., Serya, R. A. T., Ibrahim, E., Haffez, H., Soror, S. H. A., & Abouzid, K. A. M. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108514 · Cited by 5
Molecular cloning and characterisation of the PmEglin cDNA in the leech Hirudinaria sp.
Cheng, B., Shao, G.-Y., Li, Y., Tian, Q., Wang, S., & Liu, F. (2022) · Biologia · doi:10.1007/s11756-022-01277-3 · Cited by 3
Cloning, purification, and homology modeling of Histone deacetylase in Leishmania donovani
Prasanna, P., Kumar, R. K., Singh, V. K., & Upadhyay, A. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104738 · Cited by 3
Recommended Tool Compounds: Isoform- and Class-Specific Histone Deacetylase Inhibitors
Schäker‐Hübner, L., & Hansen, F. K. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00619 · Cited by 5
Role of microRNA-494 in tumor progression.
Maharati, A., Akhlaghipour, I., Taghehchian, N., Yazdi, Z. F., & Moghbeli, M. (2023) · PubMed Central · Cited by 5
Honin, I., Nováková, Z., Feller, F., Schneider, S., Schäker‐Hübner, L., Bařinka, C., & Hansen, F. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073036 · Cited by 1
Parrish, R. H. (2021) · Gastroenterology Insights · doi:10.3390/gastroent12030026 · Cited by 1
The Impact of 6-Thioguanine on Epigenetics of Acute Myeloid Leukemia
Rostamian, T., Hekmatimoghaddam, S., & Pourrajab, F. (2021) · Annals of Cancer Research and Therapy · doi:10.4993/acrt.29.121
Li, J. J. (2020) · Wiley eBooks · doi:10.1002/9781119607311.ch1
Li, L., Hao, S., Gao, M., Liu, J., Xu, X., Huang, J., Cheng, G., & Yang, H. (2023) · doi:10.1158/2326-6066.c.6573748
Li, L., Hao, S., Gao, M., Liu, J., Xu, X., Huang, J., Cheng, G., & Yang, H. (2023) · doi:10.1158/2326-6066.c.6573748.v1
Yang, Y., Zhang, Y., Lin, Z., Wu, K., He, Z., Zhu, D., Zhao, J., Zhang, C., & Fan, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19778023
Yang, Y., Zhang, Y., Lin, Z., Wu, K., He, Z., Dengyan, Z., Zhao, J., Zhang, C., & Fan, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19778020
Yang, Y., Zhang, Y., Lin, Z., Wu, K., He, Z., Dengyan, Z., Zhao, J., Zhang, C., & Fan, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19778005
Yang, Y., Zhang, Y., Lin, Z., Wu, K., He, Z., Dengyan, Z., Zhao, J., Zhang, C., & Fan, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19778011
Yang, Y., Zhang, Y., Lin, Z., Wu, K., He, Z., Dengyan, Z., Zhao, J., Zhang, C., & Fan, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19778014
Yang, Y., Zhang, Y., Lin, Z., Wu, K., He, Z., Dengyan, Z., Zhao, J., Zhang, C., & Fan, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19778017
Epigenetic Control of Stress-Induced Depression: Emerging Roles of HDAC3 and HDAC6
Mohan, A. S., Narayanan, J., Kashid, V. A., Patel, R. J., & Prajapati, B. G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167313
“As a result, there are few specific HDAC3 inhibitors [93].”
Kang, N., Zhang, Q., Zhang, X., Cheng, W., Gao, Z., Bao, T., & Zhao, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1890366
“Several HDAC inhibitors have already been approved by the U.S. Food and Drug Administration (FDA) for clinical use, including belinostat, vorinostat, romidepsin, and panobinostat, and they are primarily used in oncology (133).”
Begum, D., Regula, S., Sengar, S., Amin, S. A., Sen, D., Biswas, S., Gayen, S., Sharma, V., & Ghosh, B. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00748a
BindingDB Entry 50018471: Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
BindingDB (2024) · UC San Diego · doi:10.7270/q2tt4w4d
BindingDB Entry 50023257: Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy.
BindingDB (2026) · UC San Diego · doi:10.7270/q2t72pb0
Metadata
- Authors
- Cao, F., Zwinderman, M., & Dekker, F.
- Affiliations
- University of Groningen (NL)
- Corresponding author
- Dekker, Frank
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2018-03-02
- Volume
- 23
- Issue
- 3
- Pages
- 551
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC6017514
- OpenAlex
- W2791709427
- Cited by
- 66
- References
- 71
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 6 · 2023: 11 · 2022: 12 · 2021: 12 · 2020: 4 · 2019: 6 · 2018: 4
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- ERC (309782)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (723.012.005)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- HDAC3, HDAC3 inhibitors, selective inhibitors, epigenetic drug targets, cancer therapy, inflammation, neurodegenerative diseases
- MeSH terms
- Vorinostat, Panobinostat, Histone Deacetylase 3, Antineoplastic Agents, Histone Deacetylases, Humans, Hydroxamic Acids, Indoles, Inflammation, Isoenzymes, Neoplasm Proteins, Neoplasms, Structure-Activity Relationship, Sulfonamides, Drug Design, Neurodegenerative Diseases, Epigenesis, Genetic, Depsipeptides, Histone Deacetylase Inhibitors, Chemistry Techniques, Synthetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.